Equities research analysts forecast that Intrexon Corp (NYSE:XON) will report earnings of ($0.31) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Intrexon’s earnings. The lowest EPS estimate is ($0.35) and the highest is ($0.24). Intrexon reported earnings of ($0.26) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 19.2%. The company is expected to report its next quarterly earnings report on Wednesday, March 7th.
On average, analysts expect that Intrexon will report full-year earnings of ($1.06) per share for the current year, with EPS estimates ranging from ($1.11) to ($0.99). For the next year, analysts expect that the business will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.00) to ($0.72). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Intrexon.
Intrexon (NYSE:XON) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. Intrexon had a negative return on equity of 18.68% and a negative net margin of 66.88%.
Shares of Intrexon (NYSE XON) traded down $0.32 during mid-day trading on Friday, reaching $14.36. The company’s stock had a trading volume of 1,549,205 shares, compared to its average volume of 2,170,000. The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1,730.00, a price-to-earnings ratio of -12.82 and a beta of 1.33. Intrexon has a 12 month low of $10.26 and a 12 month high of $26.99.
In related news, CEO Randal J. Kirk bought 1,000,000 shares of the business’s stock in a transaction on Friday, January 19th. The stock was acquired at an average cost of $12.50 per share, with a total value of $12,500,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 55.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the business. Peregrine Capital Management LLC increased its stake in shares of Intrexon by 10.7% in the 4th quarter. Peregrine Capital Management LLC now owns 645,596 shares of the biotechnology company’s stock worth $7,437,000 after acquiring an additional 62,268 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Intrexon by 85.5% in the 4th quarter. SG Americas Securities LLC now owns 13,560 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 6,251 shares during the last quarter. Frontier Capital Management Co. LLC increased its stake in shares of Intrexon by 139.0% in the 4th quarter. Frontier Capital Management Co. LLC now owns 276,284 shares of the biotechnology company’s stock worth $3,183,000 after acquiring an additional 160,701 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of Intrexon in the 3rd quarter worth $121,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Intrexon in the 3rd quarter worth $1,945,000. 77.46% of the stock is owned by institutional investors and hedge funds.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.